Episurf Medical: Episurf Medical First step into the US market - DNB

Episurf recently announced that it has received its first product clearance for use on the US market. The patellofemoral implant system, for treatment of arthritis in the knee, received its 510(k) clearance in late December. This is positive as it is the company’s first step into the large US market. We expect Episurf to mainly use different distributor networks for the sales and marketing in the US and we expect to see multiple signed distribution agreements in early 2023. We reiterate our fair value for Episurf of SEK3.3–9.3.

Länk till analysen i sin helhet: https://www.dnb.no/seg-fundamental/fundamentalweb/GetReportSpon.aspx?file=CMPSP_206126.pdf